The latest cancer drugs news
Browsing: Cancer Drug News
EU approval for pembrolizumab plus paclitaxel ± bevacizumab for adult PD-L1 platinum-resistant recurrent ovarian carcinoma
The European Commission has approved pembrolizumab plus paclitaxel plus or minus bevacizumab for the treatment…
FDA approves nivolumab with chemotherapy for previously untreated Hodgkin lymphoma
On March 20, 2026, the Food and Drug Administration approved nivolumab with doxorubicin, vinblastine, and…
FDA grants traditional approval to encorafenib for metastatic colorectal cancer with a BRAF V600E mutation
On February 24, 2026, the Food and Drug Administration granted traditional approval to encorafenib (Braftovi,…
FDA approves acalabrutinib with venetoclax for chronic lymphocytic leukeamia or small lymphocytic lymphoma
On February 19, 2026, the Food and Drug Administration approved acalabrutinib tablets and capsules in…
FDA approves pembrolizumab with paclitaxel for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma
The Food and Drug Administration (FDA) has approved pembrolizumab as well as pembrolizumab and berahyaluronidase…
Cost-effectiveness of adjuvant immunotherapy varies by cancer type: new systematic review
As immunotherapy moves earlier into cancer treatment pathways, its clinical benefits are increasingly well established.…
PBS listing announced for treatment of unresectable or metastatic, well-differentiated extra-pancreatic or pancreatic neuroendocrine tumours
Ipsen Australia welcomes the Pharmaceutical Benefits Scheme (PBS) listing of Cabometyx® (cabozantinib) for the treatment…
FDA approves lisocabtagene maraleucel for relapsed or refractory marginal zone lymphoma
On December 4, 2025, the Food and Drug Administration approved lisocabtagene maraleucel for adults with relapsed…
FDA approves niraparib and abiraterone acetate plus prednisone for BRCA2-mutated metastatic castration-sensitive prostate cancer
On December 12, 2025, the Food and Drug Administration approved niraparib and abiraterone acetate with prednisone…
FDA approves epcoritamab-bysp for follicular lymphoma indications
On November 18, 2025, the Food and Drug Administration approved epcoritamab-bysp with lenalidomide and rituximab for…